Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + ivonescimab
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Chidamide + ivonescimab is an investigational combination therapy consisting of two agents with distinct mechanisms of action. Chidamide (also known as tucidinostat or HBI-8000) is a selective histone deacetylase inhibitor (HDACi) that targets HDAC1, HDAC2, HDAC3, and HDAC10. It modulates epigenetic regulation to induce cell cycle arrest and apoptosis in tumor cells and can enhance immune recognition by upregulating immune-related surface markers. Ivonescimab (AK112/SMT112) is a first-in-class bispecific monoclonal antibody targeting both programmed death-1 (PD-1) and vascular endothelial growth factor A (VEGF-A). By simultaneously blocking PD-1-mediated immunosuppression and VEGF-driven angiogenesis in the tumor microenvironment, it aims to potentiate antitumor immunity while inhibiting tumor vascularization. The combination is under clinical investigation for advanced bone sarcoma and soft tissue sarcoma as a second-line treatment[7][9].
- Other names
- chidamide + AK112tucidinostat + AK112
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on chidamide + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + ivonescimab.